Drug Alert: CDSCO flags 83 formulations as not of standard quality
In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 83 medicine batches for failing to qualify for a random drug sample test for the month of November, 2022.
These drugs samples which are declared not of standard quality include Pantop-DSR (Pantoprazole Sodium Gastro-resistant & Domperidone Prolonged- release Capsules IP) manufactured by Aristo Pharmaceuticals, SHELCAL-500 (Calcium And Vitamin D3 Tablets I.P.) manufactured by Pure and Cure Healthcare, Paracetamol Tablets IP 650mg manufactured by ANG Lifesciences India, Montelukast Sodium Tablets IP 5 mg manufactured by Skymap Pharmaceuticals and others.
For more details, check out the link given below:
83 Drug Samples Fail To Qualify CDSCO Test
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.